Skip to main content

Table 6 WTP estimates (£) at 24-month follow-up and Net Benefit analysis

From: What, who and when? Incorporating a discrete choice experiment into an economic evaluation

  All Medman trial participants Trial groups Intervention subgroups
  Intervention and control together P-vala Vs. Intervention P-vala Vs. Control Intervention Control P-vala Intervention still receiving at 24 months Intervention not receiving at 24 months P-vala
Willingness to pay (WTP)
when moving from ‘Medicines review by GP only’ to ‘Medicines review by GP & Pharmacist’
mean −26.475 <0.01 <0.01 3.52 −56.47 <0.01 41.55 −34.25 <0.01
SD 10    1.17 18.83   13.85 11.42  
Difference in societal costs from Tables 1 and 2   11.99    −11.20 +35.20   −36.73 +16.08  
Net Benefit (NB)b mean −38.47 0.44 0.30 14.72 −91.67 <0.01 78.29 −50.33 <0.01
SD 229.11    1620.60 1167.68   1706.09 1528.41  
  1. a Differences between groups at 24-month follow-up were tested using Mann–Whitney test statistics. b NB was calculated as: (WTP at 24-month follow-up, from DCE patient survey data; see Table 5) – (difference in society costs, from Medman Trial data see Tables 1 and 2)